Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTERIA I: Omalizumab in Refractory CIU/CSU
NCT01287117Phase 3Completed
- Sponsor
- Genentech
- Start
- Feb 2011
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of omalizumab in chronic spontaneous urticaria (CSU), sponsored by Genentech. Started Feb 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT01287117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287117.